tagraxofusp 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
fusion proteins 5323 2055491-00-2

Description:

MoleculeDescription

Synonyms:

  • elzonris
  • tagraxofusp
  • tagraxofusp-erzs
  • SL-401
  • DT388IL3
  • Molecule 129
Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 7, 2021 EMA STEMLINE THERAPEUTICS B.V.
Dec. 21, 2018 FDA STEMLINE THERAPEEUTICS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Capillary leak syndrome 93.22 49.58 12 48 2188 63486774

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Capillary leak syndrome 322.60 55.26 48 306 2210 34954367

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Capillary leak syndrome 348.44 58.30 50 327 3875 79740136

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX67 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA CS M0005633 Cytotoxins
FDA EPC N0000193862 Cytotoxin
FDA EPC N0000193864 CD123 Interaction
FDA MoA N0000193865 CD123 Interactions

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Blastic plasmacytoid dendritic cell neoplasm indication 445105005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Elongation factor 2 Enzyme UNKNOWN
Interleukin-3 receptor Membrane receptor BINDING AGENT UNKNOWN DRUG LABEL

External reference:

IDSource
8ZHS5657EH UNII
C4746084 UMLSCUI
CHEMBL4297573 ChEMBL_ID
DB14731 DRUGBANK_ID
D11358 KEGG_DRUG
10770 INN_ID
017871 NDDF
783435000 SNOMEDCT_US
783577002 SNOMEDCT_US
4038207 VANDF
4038208 VANDF
2109054 RXNORM
303404 MMSL
35833 MMSL
d09110 MMSL
C000592123 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Elzonris HUMAN PRESCRIPTION DRUG LABEL 1 72187-0401 INJECTION, SOLUTION 1000 ug INTRAVENOUS BLA 27 sections
Elzonris HUMAN PRESCRIPTION DRUG LABEL 1 72187-0401 INJECTION, SOLUTION 1000 ug INTRAVENOUS BLA 27 sections
Elzonris HUMAN PRESCRIPTION DRUG LABEL 1 72187-0401 INJECTION, SOLUTION 1000 ug INTRAVENOUS BLA 27 sections